Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Montana Governor Aims to Lower Drug Prices

By Drug Discovery Trends Editor | August 27, 2010

HELENA, Mont. (AP) – Gov. Brian Schweitzer, cooking up a new plan to get cheaper prescription drugs for state residents, said he wants to let every Montanan get discounted medicine through Medicaid.

It’s the latest idea from Schweitzer to either import cheaper name-brand prescriptions or to otherwise bypass what he sees as exorbitant prices charged by “drug cartels.” Previous plans have been shot down by the federal government as either illegal or impracticable.

Schweitzer, who has been critical of the health care overhaul passed by his fellow Democrats in Washington D.C., said he is drafting a federal request to let any Montanan voluntarily sign up for a special Medicaid prescription drug program.

He said Tuesday his program would let those people buy the drugs at the cheaper rate the state pays through prices negotiated by Medicaid. He will ask the federal government for an official Medicaid state plan amendment in a few weeks that he believes will cost the government nothing because it will just be passing along the discounted drugs it gets.

The Centers for Medicare and Medicaid Services said it cannot comment until it receives a formal Medicaid state plan amendment request.

“These things often change forms more than once before finally coming to us,” said agency spokeswoman Mary Kahn.

The governor made the comments Thursday in a meeting with a maker of generic drugs, Teva Pharmaceuticals USA, about ways that company could help the state use more of the cheaper medicine in favor of expensive brand-name alternatives.

The company told Schweitzer that Montana ranks well by using 71 percent generics in its state-run programs, but it pointed out Montana ranks behind leader Massachusetts, which uses 77 percent generics.

But Schweitzer’s bigger plan is to put the spotlight on the big money the pharmaceutical industry makes by charging Americans more for its products. He said Congress is partly too blame, and he aims to point it out by requesting that every Montanan be allowed to pay the same price Medicaid does for medicine.

“They can’t turn me down or they will look like they are bought and paid for by the drug lords,” Schweitzer said.

Schweitzer has previously been shot down with plans to get federal approval to bring in cheaper drugs from Canada and to buy cheaper medicine given to the U.S. Department of Veterans Affairs.

Date: August 26, 2010
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE